First-generation FLT3 inhibitors, such as sunitinib, midostaurin, lestaurtinib, sorafenib, ponatinib, and tandutinib, are multi-kinase inhibitors approved by the FDA in 2017 for the treatment of FLT3-mutated AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.